Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Arquitos Capital Management 2026 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Arquitos Capital Management)

Primary Source Intelligence • Q2 2026 Letter Analysis

Arquitos Capital Management Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Arquitos Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+64.8%

YTD+52.9%

Annualized+11.3%

Positioning StanceNEUTRAL

Market CapSmallCap

GeographyUS

Digest Analysis

Quick Take

"Driven by Liquidia's fivefold gain as its drug launch succeeded spectacularly. The concentrated portfolio approach continues to work: largest positions consistently outperform."

Executive Summary

Arquitos returned 64.8% net in Q2 2026 and 52.9% year-to-date, driven primarily by Liquidia, the fund's largest position over the past year. Liquidia shares rose fivefold from $12.46 to $79.73 as its PAH and PH-ILD drug Yutrepia achieved one of the most successful recent drug launches. The manager expects shares to reach $140 if Liquidia wins its pending patent trial against United Therapeutics outright, with a decision imminent. Abivax, a new 10% position, rebounded from $70 to above $140 after safety data dispelled cancer concerns around its ulcerative colitis drug, and the manager expects a buyout above $200 per share. Finch Therapeutics was sold through bankruptcy for a disappointing low double-digit return. The manager emphasizes that Arquitos' concentrated approach—holding only 3-5 positions for 3-6 years each—has consistently produced a strong slugging percentage where the largest, highest-conviction positions deliver the best returns. The fund has generated 17.4% annualized returns since inception by waiting for perfect pitches and swinging for the fences only when downside is protected and upside is substantial.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

92%

CautiousHigh

High Conviction (92%)

This letter demonstrates extreme conviction. The portfolio holds only 3-5 concentrated positions with Liquidia as the largest holding for the past year, sized using long-dated in-the-money call options to amplify exposure. The manager provides specific price targets ($140 for Liquidia clean win, $123 for royalty scenario, above $200 for Abivax buyout) and states he would be 'an aggressive buyer' on weakness. He explicitly defends concentration as risk-reducing when positions represent best-known, highest-conviction opportunities. The 14-year track record of only four big winners held 3-6 years each demonstrates unwavering commitment to this approach. Position sizing is explicit (10% Abivax allocation), catalysts are named and dated (imminent patent decision), and the manager's willingness to hold through volatility is stated directly. This is textbook high conviction, scoring 0.92.

Growth Outlook

60%

BearishBullish

Neutral (60%)

The manager states he 'continues to see opportunities in the market' for the rest of 2026 and 'remains confident' in portfolio holdings. He is actively fundraising and seeking to grow the fund, indicating a constructive view. However, the letter focuses primarily on specific holdings rather than broad market commentary, and there is no explicit discussion of market valuations or cycle positioning. The positive language about ongoing opportunities and confidence in holdings supports a moderately bullish score of +0.60.

Risk Appetite

75%

DefensiveAggressive

Aggressive (75%)

The portfolio is aggressively positioned with extreme concentration in 3-5 names, heavy use of long-dated call options on the largest position (Liquidia), and a new 10% allocation to Abivax including options. The manager explicitly states he would be 'an aggressive buyer' if Liquidia drops on a royalty scenario, demonstrating willingness to add to risk. The 64.8% quarterly return and 116.2% trailing twelve-month return reflect maximum long exposure in high-conviction biotech positions. This is clearly a risk-on posture, scoring +0.75.

Capital Deployment

40%

De-riskingDeploying

Net Neutral (40%)

The manager opened a new 10% position in Abivax during the quarter at $80 per share, representing moderate deployment. However, no cash level changes are disclosed, and the Finch position was exited through bankruptcy sale, potentially generating proceeds. The letter describes selective adding (Abivax) rather than broad-based deployment, and the manager is actively fundraising to grow the fund rather than deploying existing cash aggressively. The net activity appears to be moderate deployment into one new name while harvesting another, supporting a score of +0.40.

Forward Guidance

55%

CautiousExpansionary

Neutral (55%)

The manager is actively fundraising and seeking to grow the fund, indicating a deployment bias. He states he would be an aggressive buyer of Liquidia on any weakness and maintains a 10% Abivax position ahead of an expected buyout. However, the letter does not describe broad-based deployment plans or new position additions beyond the existing concentrated holdings. The forward stance is selectively bullish on current names rather than broadly deploying into new opportunities, supporting a score of +0.55.

Language Signal

70%

BearishBullish

Bullish (70%)

The letter is dominated by positive directional language: 'most successful drug launches in recent history,' 'outstanding results,' 'very strong' efficacy, 'extremely well,' shares 'should be worth $140,' buyout 'likely to be above $200,' and 'pleased with our recent results.' The manager describes Liquidia's commercial success as exceeding expectations and Abivax's safety data as vindicating his thesis. Negative language is limited to the Finch disappointment, which is framed as an acceptable outcome given protected downside. The net balance is clearly bullish, scoring +0.70.

Perceived Risk

35%

Low RiskElevated

Moderate Risk (35%)

The manager acknowledges specific event risk around the Liquidia patent decision, warning of 'likely short-term swing, either high or low' in portfolio value. He also notes the Finch disappointment and admits to underestimating legal timeline risk. However, these risks are framed as manageable and specific to individual positions rather than systemic concerns. The manager explicitly argues that concentration reduces rather than increases risk when positions are well-known and undervalued. There is no discussion of market-wide risks, valuation concerns, or macro headwinds. The risk discussion is limited to identifiable, position-specific factors, scoring 0.35.

Opportunity Density

55%

ScarceAbundant

Selective (55%)

The manager states he 'continues to see opportunities in the market' for the rest of 2026 and is actively fundraising to deploy capital, indicating a constructive view of the opportunity set. However, the letter focuses on existing concentrated holdings rather than describing a broad pipeline of new ideas. Only one new position (Abivax) was added during the quarter, and the manager's approach requires waiting for 'perfect pitches' rather than continuous deployment. This suggests selective opportunities in defined areas rather than a rich, broad opportunity set, supporting a score of 0.55.

Time Horizon

72%

Short-TermLong-Term

Decade+ (72%)

The manager explicitly describes a multi-year holding period, stating that the four big winners in the fund's history were each held for 3-6 years. He emphasizes waiting for perfect pitches and holding through volatility, consistent with a patient, long-term approach. However, the letter also focuses heavily on near-term catalysts: the imminent Liquidia patent decision and expected Abivax buyout. The use of call options on Liquidia suggests some catalyst dependency within a multi-year framework. The combination of 3-6 year typical holding periods with near-term catalyst focus supports a score of 0.72, reflecting a medium to long-term horizon with some catalyst awareness.